1. Overview of Profiling for Hemodialysis
Overview of Profiling for Hemodialysis

2. Objectives
Upon completion of this program, the participant should be able to:
Define profiled dialysis.
Discuss the goals of profiled dialysis.
Define mechanisms involved during conductivity profiling and UF profiling.
Apply what is learned to individual cases in the clinical setting.
Read the slide

3. What is Profiled Dialysis?
The manipulation of dialysate conductivity or rate of Ultrafiltration (UF)
The goal of profiled dialysis is:
To control sodium and fluid removal
To maintain patient equilibrium
To minimize or eliminate the side effects of dialysis

4. Why Use Dialysis Profiling?
Patients may survive longer
Improves tolerance to dialysis treatments
Currently in dialysis treatments without Profiling, there is a 30% - 40% incidence of side effects, including:
Nausea, vomiting
Hypotension
Angina
Cramping
Vascular Instability
Applying profiling to dialysis treatments may reduce or eliminate untoward treatment side effects.

5. Patient Symptoms: Hypotension Headache and Loss of Consciousness
Cramping
Angina
Nausea and Vomiting

6. Hypotension in HD Contributing factors : Decreased cardiac reserve
The ability of the heart to respond to the body’s needs
Contributing factors :
Decreased cardiac reserve
Declining plasma osmolality
High UF rates, volume depletion
Antihypertensive drugs
Autonomic nerve dysfunction
Sodium and solute loss
Blood vessels do not respond to low blood pressure

7. Treatment of Hypotension
Assess “dry” weight accurately
Assure the correct dialysate concentrations
Na+ > 140 mEq/l, bicarbonate buffer
Use of sequential UF then dialysis
Others
Lower dialysate temp from 37ºC to 35ºC
Proper positioning the patient
Normal saline bolus
Hypertonic saline
And now, you can add Conductivity Profiling and/or Ultrafiltration Profiling to your list of treatment options.

8. A Better Way to Better Careor
Visit us at
Caution: Federal Law (USA) restricts this device to sale, by or on the order of a physician
Read Instructions for Use prior to patient application
Trademarks used herein are owned by or licensed to Gambro.Inc
Gambro © 2007
Rev D